

MCI CLINICAL TRIALS ACTIVITY

10/1/2020 TO 9/30/2021

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	BUDGET PERIOD	BUDGET AWARDS
UNIT: Mitchell Cancer Institute							
MCI Clinical Trials							
Alkharabsh	Omar	ABVI	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance	A21-0019-001	New	10/26/2020 9/30/2021	\$24,135
Alkharabsh	Omar	NIH	A Phase III, Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly	A21-0034-001	New	10/1/2020 3/1/2024	\$0
Khushman,	Moh'D	NIH	Phase I/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)	A20-0205-001	New	6/1/2020 5/31/2021	\$0
Khushman,	Moh'D	MERCK	MK7339-012 A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by	A20-0213-001	New	9/30/2020 9/29/2021	\$0
Khushman,	Moh'D	NIH	A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer	A21-0037-001	New	11/2/2020 11/30/2030	\$0
Poosarla,	Teja	OBI	Alpha Oncology, Inc./Oncolytics Biotech CDA	A20-0214-001	New	9/30/2020 9/29/2021	\$11,000
Rocconi,	Rodney	NIH	EAY131 - Molecular Analysis for therapy choice (MATCH) - Credit NRG	A16-0056-003	Continuation	5/31/2019 2/28/2021	\$84,000
TOTAL FOR DEPARTMENT: MCI Clinical Trials							\$119,135